Amplifications and rare activating mutations of EGFR and overexpression of HER2, KIT, BCL2 and TP53, as well as loss of CDKN2A have been previously described.7, 10 However, no strong evidence supports response of thymomas to EGFR or KIT targeted therapies.11 Here, KIT is linked to thymoma.